Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
24.87
-0.12 (-0.48%)
Aug 14, 2025, 2:24 PM - Market open
Celldex Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 23.04 | 28.36 | 34.81 | 29.43 | 39.14 | 43.84 | Upgrade
|
| Short-Term Investments | 607.29 | 696.93 | 388.78 | 275.52 | 369.11 | 150.59 | Upgrade
|
| Cash & Short-Term Investments | 630.34 | 725.28 | 423.6 | 304.95 | 408.25 | 194.42 | Upgrade
|
| Cash Growth | -21.44% | 71.22% | 38.91% | -25.30% | 109.98% | 201.98% | Upgrade
|
| Receivables | 0.09 | 0.7 | 2.63 | 0.35 | 0.17 | 1.8 | Upgrade
|
| Prepaid Expenses | 17.98 | 21.18 | 5.47 | 12.39 | 2.42 | 1.62 | Upgrade
|
| Total Current Assets | 648.4 | 747.16 | 431.69 | 317.69 | 410.84 | 197.84 | Upgrade
|
| Property, Plant & Equipment | 7.51 | 8.24 | 6.64 | 7.75 | 6.52 | 7.26 | Upgrade
|
| Other Intangible Assets | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 30.69 | Upgrade
|
| Other Long-Term Assets | 9.3 | 9.75 | 0.11 | 0.1 | 0.1 | 0.04 | Upgrade
|
| Total Assets | 692.41 | 792.34 | 465.63 | 352.74 | 444.65 | 235.84 | Upgrade
|
| Accounts Payable | 2.07 | 3.27 | 3.49 | 3.34 | 1.23 | 1.05 | Upgrade
|
| Accrued Expenses | 28.42 | 33.84 | 22.03 | 12.84 | 12 | 8.46 | Upgrade
|
| Current Portion of Leases | 1.54 | 1.45 | 1.61 | 1.45 | 1.75 | 1.33 | Upgrade
|
| Current Unearned Revenue | - | 0.01 | 3.06 | 0.06 | 0.43 | - | Upgrade
|
| Other Current Liabilities | 0.93 | 0.93 | 0.93 | 0.93 | 1.12 | 3.37 | Upgrade
|
| Total Current Liabilities | 32.96 | 39.5 | 31.13 | 18.61 | 16.53 | 14.21 | Upgrade
|
| Long-Term Leases | 1.5 | 2.36 | 0.93 | 2.59 | 1.3 | 2.15 | Upgrade
|
| Other Long-Term Liabilities | 2.54 | 3.47 | 4.4 | 5.33 | 7.35 | 10.12 | Upgrade
|
| Total Liabilities | 37 | 45.34 | 36.46 | 26.53 | 25.18 | 26.48 | Upgrade
|
| Common Stock | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 2,318 | 2,299 | 1,823 | 1,581 | 1,561 | 1,280 | Upgrade
|
| Retained Earnings | -1,666 | -1,555 | -1,397 | -1,256 | -1,144 | -1,073 | Upgrade
|
| Comprehensive Income & Other | 3.34 | 3.31 | 3.31 | 1.26 | 1.89 | 2.59 | Upgrade
|
| Shareholders' Equity | 655.41 | 747.01 | 429.17 | 326.2 | 419.48 | 209.36 | Upgrade
|
| Total Liabilities & Equity | 692.41 | 792.34 | 465.63 | 352.74 | 444.65 | 235.84 | Upgrade
|
| Total Debt | 3.03 | 3.81 | 2.54 | 4.03 | 3.04 | 3.48 | Upgrade
|
| Net Cash (Debt) | 627.31 | 721.47 | 421.06 | 300.92 | 405.21 | 190.94 | Upgrade
|
| Net Cash Growth | -21.58% | 71.35% | 39.92% | -25.74% | 112.22% | 214.43% | Upgrade
|
| Net Cash Per Share | 9.45 | 11.20 | 8.69 | 6.42 | 9.45 | 6.44 | Upgrade
|
| Filing Date Shares Outstanding | 66.41 | 66.38 | 55.9 | 47.21 | 46.74 | 39.61 | Upgrade
|
| Total Common Shares Outstanding | 66.39 | 66.37 | 55.88 | 47.2 | 46.73 | 39.6 | Upgrade
|
| Working Capital | 615.44 | 707.66 | 400.57 | 299.08 | 394.31 | 183.64 | Upgrade
|
| Book Value Per Share | 9.87 | 11.25 | 7.68 | 6.91 | 8.98 | 5.29 | Upgrade
|
| Tangible Book Value | 628.22 | 719.82 | 401.98 | 299.01 | 392.29 | 178.67 | Upgrade
|
| Tangible Book Value Per Share | 9.46 | 10.84 | 7.19 | 6.33 | 8.39 | 4.51 | Upgrade
|
| Machinery | - | 17.39 | 16.01 | 15.26 | 14.51 | 14.61 | Upgrade
|
| Construction In Progress | - | 0.14 | 0.79 | 0.5 | 0.63 | 0.34 | Upgrade
|
| Leasehold Improvements | - | 10.29 | 9.65 | 9.61 | 9.53 | 10.1 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.